简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
01
2024-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
29
2024-02
Notification Letter to Non-registered H Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
29
2024-02
Notification Letter to Registered H Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
01
2024-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
30
2024-01
Voluntary Announcement Authorization to Zencore Biologics to use BA-HIEXcell Stable Cell Line Development Platform
26
2024-01
Voluntary Announcement Exclusive License Agreement for BA2101 in the Treatment of Respiratory System Diseases
24
2024-01
Voluntary Announcement both BA1105 and BA1301 being Granted Orphan Drug Designations for Treatment of Gastric Cancer by FDA
17
2024-01
Voluntary Announcement the Company has Obtained GMP Certification for Boyuno from the Brazilian Agencia Nacional de Vigilancia Sanitaria
04
2024-01
Voluntary Announcement Enrollment of Subjects Completed for International Multi-Center Comparative Clinical (Phase 3) Study of Denosumab Injection
03
2024-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
4
5
6
7
8
Follow me
鲁公网安备37069102000284